Net revenue of approximately $154.9 million for full-year 2025. ZYNRELEF® delivered the largest quarter-over-quarter revenue increase within the portfolio in Q4 (up ~35% vs Q3 2025). About CINVANTI® ...
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results